Original language | English (US) |
---|---|
Pages (from-to) | 2138-2142 |
Number of pages | 5 |
Journal | Blood |
Volume | 138 |
Issue number | 21 |
DOIs | |
State | Published - Nov 25 2021 |
ASJC Scopus subject areas
- Hematology
- Biochemistry
- Cell Biology
- Immunology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. / Rossoff, Jenna; Baggott, Christina; Prabhu, Snehit et al.
In: Blood, Vol. 138, No. 21, 25.11.2021, p. 2138-2142.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia
AU - Rossoff, Jenna
AU - Baggott, Christina
AU - Prabhu, Snehit
AU - Pacenta, Holly
AU - Phillips, Christine L.
AU - Stefanski, Heather
AU - Talano, Julie An
AU - Moskop, Amy
AU - Margossian, Steven P.
AU - Verneris, Michael R.
AU - Myers, Gary Douglas
AU - Karras, Nicole
AU - Brown, Patrick A.
AU - Qayed, Muna
AU - Hermiston, Michelle
AU - Satwani, Prakash
AU - Krupski, Christa
AU - Keating, Amy K.
AU - Wilcox, Rachel
AU - Rabik, Cara A.
AU - Fabrizio, Vanessa A.
AU - Kunicki, Michael
AU - Chinnabhandar, Vasant
AU - Goksenin, A. Yasemin
AU - Curran, Kevin J.
AU - Mackall, Crystal L.
AU - Laetsch, Theodore W.
AU - Schultz, Liora M.
N1 - Funding Information: Conflict-of-interest disclosure: C.L.P. has served on an advisory committee for Novartis. H.S. has served on an advisory committee and as a member of the Speakers Bureau for Novartis. S.P.M. has served on an advisory committee for Novartis and Jazz Pharmaceuticals. M.R.V. has served on an advisory committee for Novartis, has been a consultant for and is a current equity holder in Fate Therapeutics and B-MoGen Biotechnologies, and has been a consultant for UpToDate. G.D.M. has served on the ELIANA trial Steering Committee and Speakers Bureau and has served as a consultant and received honoraria from Novartis. P.A.B. has served on an advisory committee for Novartis, Kite, Takeda, Janssen, Kura, Servier, and Jazz Pharmaceuticals. M.Q. has served as a consultant for Novartis and Mesoblast. M.H. has served on an advisory board for Sobi and Novartis. P.S. has served as a consultant for Takeda and Mesoblast. K.J.C. has served as a consultant for and received research funding from Novartis, has served as a consultant for Mesoblast, and received research funding from Celgene. C.L.M. has served as a consultant for and is a current equity holder in Lyell Immunopharma and Apricity Health, has served as a consultant for NeoImmune Tech, Nektar Therapeutics, and Bristol Myers Squibb, and is a current equity holder in Allogene. T.W.L. reports consultancy relationships with Novartis, Cellectis, Bayer, Deciphera, Jumo Health, and Y-mAbs Therapeutics and has received research funding from Pfizer, Novartis, and Bayer. The remaining authors declare no competing financial interests.
PY - 2021/11/25
Y1 - 2021/11/25
UR - http://www.scopus.com/inward/record.url?scp=85119700502&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119700502&partnerID=8YFLogxK
U2 - 10.1182/blood.2021012392
DO - 10.1182/blood.2021012392
M3 - Letter
C2 - 34499715
AN - SCOPUS:85119700502
SN - 0006-4971
VL - 138
SP - 2138
EP - 2142
JO - Blood
JF - Blood
IS - 21
ER -